Arcus Biosciences Q4 EPS $(0.89) Beats $(1.03) Estimate, Sales $33.000M Miss $35.711M Estimate
Benzinga Newsdesk 8 months ago
EarningsEarnings BeatsEarnings MissesNews
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(1.03) by 13.51 percent. This is a 13.59 percent increase over losses of $(1.03) per share from
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(1.03) by 13.51 percent. This is a 13.59 percent increase over losses of $(1.03) per share from the same period last year. The company reported quarterly sales of $33.000 million which missed the analyst consensus estimate of $35.711 million by 7.59 percent. This is a 8.33 percent decrease over sales of $36.000 million the same period last year.